Objective. Anal cancer rates have increased in HIV+ patients. The prevalence of anal intraepithelial neoplasias (AINs) and progression to anal cancer in HIV+ men who have sex with men has been well described, and screening is cost-effective. Our objective was to determine whether anal cancer screening in HIV+ women is cost-effective.
A nal cancer rates in the United States have increased in both men and women. Approximately, 1 in 610 people will be diagnosed with anal cancer in their lifetime [1] . Overall, women have higher rates of invasive anal cancer compared to men (1.8 vs 1.4/100,000); however, women have a higher survival rate (69% vs 58%) [1Y4] . Anal cancer is rarer than cervical cancer, which affects 8 in 100,000 women [5] . Increased rates of anal cancer may be secondary to increased number of lifetime partners [4] . Risk factors for anal intraepithelial neoplasia (AIN) and cancer include tobacco abuse, multiple sexual partners, history of sexually transmitted infections, receptive anal intercourse, genital and anal warts, immunosuppression, anal human papillomavirus (HPV) infection, and human immunodeficiency virus (HIV) infection [4, 6Y9] . Human papillomavirusYrelated anal squamous cell cancer rates have increased in adults with HIV and acquired immune deficiency syndrome (AIDS) despite effective antiretroviral (ARV) therapy [3, 5Y8, 10] .
Increased rates of anal cancer in HIV-positive individuals may be explained by improved life expectancy, high prevalence of HPV, and increased rates of persistent HPV infection [3, 7, 11] . Risk factors for increased anal cancer rates in HIV-positive patients are low CD4 counts and high plasma viral loads [3, 10, 12] . In comparison to immunocompetent patients, HIV-positive individuals have faster rates of progression from AIN to cancer [3] . As a result of increased prevalence and rates of progression to cancer, anal cytology may serve as an effective screening tool in HIV-positive patients at risk for anal cancer [2, 6, 13, 14] .
Similar to cervical cancer screening, cytology can be used to detect anal HPV infection and intraepithelial neoplasia [2] . Anal intraepithelial neoplasia may be less likely to progress to cancer and progression rates from high-grade AIN (HGAIN) to cancer may be slower than those in the cervix [13] . Previous studies have shown that the sensitivity and specificity of anal cytology are lower in women than in men who have sex with men (MSMs). High-resolution anoscopy (HRA) has 100% sensitivity and 71% specificity for the detection of AIN, but the cost of HRA remains high [15] . Therefore, a stepwise screening approach of abnormal cytologic result followed by reflex HRA and biopsy is warranted [2, 3, 15] .
When compared to HIV-negative women, HIVpositive women have a 6.8 (95% confidence interval = 2.7Y14) increased risk for anal cancer [2, 3, 14, 15] . Approximately 26% of HIV-positive women have abnormal anal cytologic result, which is more common than cervical intraepithelial neoplasia in this population [2, 3, 7] . Risk factors associated with increased rates of AIN in HIV-positive women include age younger than 40 years, tobacco abuse, ARV use, AIDS-defining illness, pelvic inflammatory disease, concurrent cervical or genital intraepithelial neoplasia, and a history of abnormal cervical cytologic result [2, 7, 16] . Although the prevalence of the stages of AIN in HIV-positive women has been described, the rates of progression from dysplasia to anal cancer are not known [3, 7] . Compared to HIV-positive MSMs, HIV-positive women have a similar risk of AIN and cancer (14Y42 vs 12/100,000) [2, 14] . Anal cancer screening has been shown to be costeffective in HIV-positive MSMs [14] . Our objective was to determine whether anal cancer screening with anal cytology and HRA is cost-effective in HIV-positive women.
MATERIALS AND METHODS
Markov models are useful for representing a changing set of health states over time when there are known probabilities for the rate of transition from one health state to another (i.e., progression from intraepithelial neoplasia to cancer) [17] . To create a cost-effectiveness model for AIN and cancer screening in HIV-positive women, we developed a Markov state-transition model to calculate lifetime costs, life expectancy, and qualityadjusted life expectancy for 3 anal cancer screening strategies. Screening strategies included no screening, annual anal cytology, and biennial anal cytology. From a previous model in MSMs developed by Goldie et al. [6] , anal cytology was most cost-effective in advanced HIV disease (CD4 G0.20 Â 10 9 /L). The Medical University of South Carolina (MUSC) Office of Research Integrity does not consider the use of theoretical models as human research and did not require institutional review board approval for this study. . Model variables were varied by 50% decrease and increase in value. Note the only variable that was not cost-effective was the progression rate of HGASIL to anal cancer, when the rate was decreased by 50%.
All 100 women in our model were assumed to have advanced HIV (CD4 G0.20 Â 10 9 /L) and to be taking ARVs. Morbidity and mortality consequences were captured using quality-adjusted life years (QALYs). Future costs and QALYs were discounted at an annual rate of 3%. Assumptions of the model were examined in a sensitivity analysis. These assumptions included rates of progression of AIN to cancer, anal cancer and HIV mortality, and the costs of anal cancer screening, the costs of treatment of AIN and cancer, and the cost of HIV disease (see Figure 1 ).
Our Markov model depicts the natural history of AIN in HIV-positive women. The health states of anal cytology used were normal (no dysplasia), low-grade anal squamous intraepithelial lesion (LGASIL), highgrade ASIL (HGASIL), and anal squamous cell cancer (ASCC). Atypical squamous cells of undetermined significance was combined into the LGASIL health state. One hundred women began the model as unscreened and were distributed into the anal cytology health states according to previously described ASIL prevalence in HIV-positive women from the Women's Interagency HIV Study, a natural-history cohort study of HIV disease in women [2] (see Table 1 ). Women were cycled through the model using monthly transition probabilities to determine regression and progression rates between anal cytology health states. Progression and regression rates of AIN were based on those used in a previous model of HIV-positive MSMs undergoing anal cancer screening [6] . Our model accounted for a 5-year period, and each Markov cycle was 12 months. Base case values are displayed in Table 2 .
To create the Markov model to simulate the natural history of AIN, several assumptions were required. We assumed the 5-year survival rate of ASCC to be 56% [14] . We assumed that HIV-positive women would have similar rates of regression of AIN to normal and progression to cancer as HIV-positive MSMs have. For example, more than 50% AIN 1 regresses to normal during 2 years. We assumed that treatment of HGAIN reduced progression to invasive ASCC by 75%. The HIV 5-year survival rate was assumed to be 86%. We assumed that the mortality per 100 of HIV-positive women with CD4 cell counts less than 0.2 Â 10 9 /L was 2.24 [6, 14] .
When cycling through the model, all women with abnormal anal cytologic result received colposcopicguided HRA and biopsy. After pathologic diagnosis of low-grade AIN (LGAIN), patients were monitored with repeat cytology at 6 and 12 months. Patients with HGAIN were treated with surgical excision and then followed with repeat cytology at 6 and 12 months. The model's management of AIN was based on the recommendations of the Centers for Disease Control and Prevention guidelines for opportunistic infections in HIV-positive individuals [18] . The recurrence of AIN is common among HIV-positive individuals, and based on the assumed treatment efficacy of surgical excision of HGAIN, the model did account for recurrent HRA and biopsy and repeat surgical therapy in cases of persistent AIN. There are currently no evidence-based guidelines for the treatment and monitoring of AIN. This model used surgical resection as therapy for HGAIN. Invasive ASCC was initially treated with surgery followed by chemotherapy and radiation. The costs of cytology, HRA and biopsy, surgical excision, and cancer therapy were determined using published medical costs [19] . Owing to lag in publication as a reflection of current costs, we used an inflation rate of 2.12 derived from the Bureau of Labor and Statistics for Medical Care (see Table 3 ). Markov models were created for the 3 approaches: no screening, annual, and biennial screening. We calculated total cost and QALYs for all 3 screening approaches.
Incremental cost-effectiveness ratios (ICERs) indicate the cost required to generate the equivalent of 1 additional year of perfect health [20] . The ICER for anal cancer screening versus no screening represents the extra cost paid for each extra unit of health improvement (QALY) gained by screening. The ICERs were calculated by comparing the difference in costs of the therapeutic strategy (screening) and the alternative strategy (no screening) and the difference the QALYs between the 2 strategies. Discounted costs were also determined using a discount rate of 0.3% (0.03). Discounting cost was done to account for future inflation and the change in the value of health care dollars [21] . The ICERs less than $100,000 were considered cost-effective, and an ICERs less than $50,000 were considered very costeffective [20] (see Table 4 ).
A sensitivity analysis was performed by varying the costs used in the model. These costs included HIV care, anal cytology, HRA and anal histology, cost of HGAIN management, and anal cancer treatment. These values were changed by 50% decrease and increase in costs. The sensitivity analysis also accounted for varying rates of 5-year HIV survival, 5-year anal cancer survival, progression of LGAIN to HGAIN, progression of HGAIN to anal cancer, and differing QALY values for HIV and anal cancer health states. These values were also adjusted for 50% decrease and increase (see Figure 1) .
RESULTS
Anal cancer screening with biennial anal cytology was cost-effective. For a group of 100 women undergoing biennial anal cancer screening, QALYs were increased by 4.4 and cost was increased by $154,010. The ICER of $34,763 was cost-effective compared to no screening. After a 3% discount, the ICER was $35,806 and remained cost-effective. Annual screening was not costeffective. The QALYs were increased by 4.4 with increased costs of $481,852, resulting in an ICER of $108,763 and 3% discounted ICER of $112,026 (see Table 4 ).
A sensitivity analysis of the biennial model was performed to determine if model remained cost-effective despite variations in rates of progression of AIN, screening costs, and HIV and cancer mortality. Values for these assumptions were varied by 50% increase and decrease. The model remained cost-effective when changing all assumptions except for when the progression rate of AIN 2,3 to ASCC was decreased by 50%. The ICER for a model with a decreased rate of progression from AIN 2, 3 to ASCC was $102,417 (see Figure 1 ). Goldie et al. [6] determined that annual and biennial anal cancer screening were cost-effective in HIV-positive MSMs. Their model suggests that annual screening is more cost-effective in homosexual and bisexual male patients with advanced HIV disease (CD4 G0.20 Â 10 9 /L).
DISCUSSION
Our model failed to demonstrate cost-effectiveness of an annual screening approach in women with advanced HIV disease [6] . This is most likely due to both an overall low incidence of anal cancer in women and slow progression rates of AIN to cancer [8, 13, 14] . The prevalence of AIN and cancer in our population of women was 61% lower than in HIV-positive MSMs, which is consistent with previously reported rates [2] . This lower prevalence of disease would decrease the effectiveness of any screening technique and impact the cost-effectiveness.
Our sensitivity analysis also demonstrates the impact of progression rates on cost-effectiveness. When Cost of screening strategy for 100 women during a 5-year cycle. b Incremental cost-effectiveness ratio determined by (total cost of screening strategy j total cost of no screening) / (QALYs screening j QALYs no screening).
progression rates from HGAIN to cancer were decreased, biennial screening was no longer cost-effective. This is consistent with findings in HIV-positive MSMs, in which decreased progression from LGAIN to HGAIN decreased cost-effectiveness [6] . Otherwise, our sensitivity analysis demonstrated a robust cost-effectiveness in biennial screening while varying other model assumptions. Therefore, our findings are consistent with those of Goldie et al. in that anal cancer screening is costeffective in high-risk HIV-positive individuals, but screening can be less frequent in women than men. Weaknesses of our study are secondary to lack of data in this population as well as model assumptions. Although prevalence of AIN has been documented in HIV-positive women, rates of progression to cancer and regression to normal are not known. Prevalence of AIN may change based on CD4 count, but the available data for HIV-positive women do not differentiate by immunocompetent status [2, 7] . As a result, we made the assumption that progression and regression rates would be similar to those chosen for a previous model in HIVpositive MSMs, which extrapolated data from progression and regression rates of cervical intraepithelial neoplasia in women [6] . Therefore, both of these models operate on this assumption, and conclusions may be altered with prospective data on anal dysplasia and cancer in HIV-positive individuals.
Our study also assumed that the women in this model had advanced HIV measured by CD4 cell counts less than 0.2 Â 10 9 /L. We assumed these women were normally compliant and were taking ARVs. We chose to do this given that these women would most likely not be enrolled in preventative screening if they were not enrolled in care. However, in reality, HIV-positive women with advanced disease may undergo cervical and breast cancer screening without actively taking ARVs. Future studies of the impact of ARVs and compliance would be beneficial regarding prevalence and progression of anal dysplasia. We also used a conservative measurement of anal cancer 5 year survival (56%). Five-year survival may improve as treatment strategies and physician awareness in at risk populations improves and patients are enrolled in treatment earlier in disease [4] . Survival for HIV disease for our model was assumed to be 86% at 5 years, which may increase with improved HIV treatment. Increased life expectancy of HIV-positive patients may lead to increased rates of anal cancer in this population. However, our sensitivity analysis demonstrated that increasing or decreasing survival in anal cancer or HIV by 50% did not alter the cost-effectiveness of biennial screening. We also assumed that treatment of HGAIN was 75% effective in reducing a risk for anal cancer, which may be an overestimate. If treatment is less than half as effective as this estimate, biennial screening is no longer cost-effective.
Our model does not account for the differences in costs among acceptable methods of treatment of HGAIN. Multiple approaches for HGAIN management have been reported in small open-labeled studies. These include photodynamic therapy, 5-fluorouracil, infrared coagulation, cryotherapy, laser, and surgical excision. There are no randomized controlled clinical trials to compare the efficacy of available AIN treatments; therefore, evidence is insufficient to recommend one over the other [18] . Given that surgical excision is the treatment of choice of HGAIN in our institution and the most expensive, we chose this conservative approach for the model. Other methods of treatment, such as infrared coagulation, can be performed in the office and are less costly. Using less costly treatment of HGAIN in our model would have only improved cost-effectiveness of AIN diagnosis and treatment.
Our study does not address anal cancer screening in HIV-negative patients or other at-risk populations. Such groups may include women with gynecologic HPV-associated cancers, transplant recipients, patients with anogenital warts, smokers, and a history of receptive anal intercourse. In a previous study of women with genital HPV-associated cancers, 12.2% (95% confidence interval = 8%Y17%) had biopsy-proven AIN [15] . More information is needed regarding rates of subsequent anal cancer in these populations to determine whether screening is feasible.
There remains much to learn regarding anal cancer screening in at risk populations. Data are needed regarding the effect of screening on survival in HIVpositive individuals. Prospective data on rates of AIN regression and progression to cancer in HIV-positive women and heterosexual men are needed. The effect of CD4 cell count, HIV plasma viral load, and ARV use on dysplasia prevalence and progression could be used to determine which HIV individuals are most at risk for developing anal cancer to target screening. Similar to the cervical cancer screening programs, efforts are needed to standardize pathologic interpretation and nomenclature of anal cytologic findings. Guidelines regarding frequency of anal cancer screening and management of intraepithelial neoplasia are also needed. Our study supports biennial anal cancer screening in HIV-positive
